Invention Grant
- Patent Title: CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
-
Application No.: US15789828Application Date: 2017-10-20
-
Publication No.: US10975158B2Publication Date: 2021-04-13
- Inventor: Sherie L. Morrison
- Applicant: The Regents of the University of California
- Applicant Address: US CA Oakland
- Assignee: The Regents of the University of California
- Current Assignee: The Regents of the University of California
- Current Assignee Address: US CA Oakland
- Agency: Weaver Austin Villeneuve & Sampson LLP
- Agent Tom Hunter
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K14/56 ; A61K38/21 ; A61K39/395 ; A61K45/06 ; C07K16/30 ; A61K39/00 ; A61K38/00 ; A61P35/00 ; C07K14/565 ; C07K14/57
Abstract:
In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CD138 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CD138 antibody attached to an interferon alpha (IFN-α) or to a mutant interferon alpha.
Public/Granted literature
- US20180162948A1 CD138-TARGETED INTERFERON DEMONSTRATES POTENT APOPTOTIC AND ANTI-TUMOR ACTIVITIES Public/Granted day:2018-06-14
Information query
